Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1939 1
1968 1
1972 1
1973 8
1974 4
1975 2
1976 2
1977 4
1978 3
1979 1
1980 7
1981 8
1982 13
1983 13
1984 11
1985 18
1986 16
1987 17
1988 7
1989 24
1990 33
1991 24
1992 25
1993 24
1994 19
1995 16
1996 17
1997 23
1998 19
1999 17
2000 16
2001 15
2002 12
2003 19
2004 6
2005 5
2006 10
2007 9
2008 6
2009 8
2010 5
2011 11
2012 10
2013 9
2014 7
2015 15
2016 11
2017 11
2018 6
2019 15
2020 10
2021 19
2022 15
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

616 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Among authors: harrison mr. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: harrison mr. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A. Tykodi SS, et al. Among authors: harrison mr. J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844. J Immunother Cancer. 2022. PMID: 35210307 Free PMC article. Clinical Trial.
Presidential Forum.
Ellison EC, Ponsky JL, Harrison MR, McGrath MH, Angelos P, Krummel TM. Ellison EC, et al. Among authors: harrison mr. Ann Surg. 2019 Oct;270(4):573-584. doi: 10.1097/SLA.0000000000003421. Ann Surg. 2019. PMID: 31274654 No abstract available.
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI. Tannir NM, et al. Among authors: harrison mr. Clin Cancer Res. 2021 Jan 1;27(1):78-86. doi: 10.1158/1078-0432.CCR-20-2063. Epub 2020 Sep 1. Clin Cancer Res. 2021. PMID: 32873572 Free PMC article.
Minimally Invasive Fetal Surgery.
Graves CE, Harrison MR, Padilla BE. Graves CE, et al. Among authors: harrison mr. Clin Perinatol. 2017 Dec;44(4):729-751. doi: 10.1016/j.clp.2017.08.001. Epub 2017 Sep 23. Clin Perinatol. 2017. PMID: 29127956 Review.
Fetal surgical therapy.
Adzick NS, Harrison MR. Adzick NS, et al. Among authors: harrison mr. Lancet. 1994 Apr 9;343(8902):897-902. doi: 10.1016/s0140-6736(94)90012-4. Lancet. 1994. PMID: 7908362 Review. No abstract available.
Prenatal cellular transplantation.
Albanese CT, Harrison MR. Albanese CT, et al. Among authors: harrison mr. Semin Pediatr Surg. 1999 Aug;8(3):101-8. doi: 10.1016/s1055-8586(99)70010-7. Semin Pediatr Surg. 1999. PMID: 10461322 Review.
Diagnosing intussusception.
de Lorimier AA, Harrison MR. de Lorimier AA, et al. Among authors: harrison mr. West J Med. 1986 Jun;144(6):741-2. West J Med. 1986. PMID: 3727534 Free PMC article. No abstract available.
Biomaterials in fetal surgery.
Winkler SM, Harrison MR, Messersmith PB. Winkler SM, et al. Among authors: harrison mr. Biomater Sci. 2019 Aug 1;7(8):3092-3109. doi: 10.1039/c9bm00177h. Epub 2019 May 17. Biomater Sci. 2019. PMID: 31099350 Free PMC article. Review.
616 results